$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Rapport Therapeutics, Inc. Common Stock (RAPP)RAPP

Rapport Therapeutics, Inc. Common Stock

$20.84

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Upturn Stock price based out of last close

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

09/18/2024: RAPP (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Upturns

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Profit: 0%	Upturn Advisory Performance 1	Avg. Invested days: 0
Profits based on simulation	Stock Returns Performance 1	Last Close 09/18/2024

Type: Stock	Today’s Advisory: PASS
Profit: 0%	Avg. Invested days: 0
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 09/18/2024	Upturn Advisory Performance 1

Key Highlights

Company Size ETF	Market Capitalization 0 USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 113311	Beta -
52 Weeks Range 16.55 - 28.08	Updated Date 09/15/2024

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 113311	Beta -
52 Weeks Range 16.55 - 28.08	Updated Date 09/15/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating 5	Target Price -	Buy -
Strong Buy 3	Hold -	Sell -
Strong Sell -

Rating 5	Target Price -	Buy -	Strong Buy 3
Hold -	Sell -	Strong Sell -

About Rapport Therapeutics, Inc. Common Stock

Exchange	NASDAQ	Headquaters	Boston, MA, United States
IPO Launch date	2024-06-07	CEO, President, Treasurer & Director	Mr. Abraham N. Ceesay M.B.A.
Sector	Healthcare	Website	https://www.rapportrx.com
Industry	Biotechnology	Full time employees	-
Headquaters	Boston, MA, United States
CEO, President, Treasurer & Director	Mr. Abraham N. Ceesay M.B.A.
Website	https://www.rapportrx.com
Website	https://www.rapportrx.com
Full time employees	-

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.